Subtype
Glioblastoma
CI-CAN-00000934GBMExplore in graph →
486 active trials2 approved drugs43 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000934GBMExplore in graph →
Clinical trials
1,750 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (281)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01666600 | NOA-12: BIBF1120 and R-RT in Glioblastoma | terminated | Phase 1 / Phase 2 | 63 | Prof. Dr. Wolfgang WickOTHER | 1 | Nov 1, 2017 | clinicaltrials |
| NCT01866449 | Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme | completed | Phase 2 | 24 | University of UlmOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT00045708 |
| A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas |
| completed |
| Phase 1 / Phase 2 |
| 57 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Oct 18, 2017 |
| clinicaltrials |
| NCT03310372 | Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme(TEMOFRAC) | completed | Phase 2 | 46 | Central Hospital, Nancy, FranceOTHER | 0 | Oct 17, 2017 | clinicaltrials |
| NCT01759810 | Proteome-based Personalized Immunotherapy of Glioblastoma | unknown | Phase 2 / Phase 3 | 60 | NeuroVita ClinicOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT01310868 | Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma | completed | Phase 2 | 59 | University College, LondonOTHER | 1 | Oct 5, 2017 | clinicaltrials |
| NCT01508117 | Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients | terminated | Phase 2 | 1 | University of CincinnatiOTHER | 1 | Sep 19, 2017 | clinicaltrials |
| NCT00187486 | Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors | completed | Phase 2 | 66 | University of California, San FranciscoOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT02029573 | Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma(ART) | completed | Phase 2 | 36 | King Fahad Medical CityOTHER_GOV | 1 | Aug 18, 2017 | clinicaltrials |
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | completed | Phase 1 / Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00980343 | GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00540722 | Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2017 | clinicaltrials |
| NCT01465347 | Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 59 | Diffusion Pharmaceuticals IncINDUSTRY | 1 | Jul 14, 2017 | clinicaltrials |
| NCT03212235 | Hypofractionated Radiation Therapy for Glioblastoma | unknown | Phase 2 | 58 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT00823797 | Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma | completed | Phase 2 | 45 | University of WashingtonOTHER | 1 | Jul 7, 2017 | clinicaltrials |
| NCT01290263 | Amgen 386 for Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01413438 | Bevacizumab With or Without Surgery for Adult Glioblastomas | withdrawn | Phase 2 | 0 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 0 | Jul 2, 2017 | clinicaltrials |
| NCT00112866 | Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme | terminated | Phase 2 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00392171 | The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601) | completed | Phase 2 | 120 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT00684567 | Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED) | completed | Phase 2 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 7, 2017 | clinicaltrials |
| NCT01310855 | Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma | terminated | Phase 2 | 38 | University College, LondonOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT00345163 | A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)(BRAIN) | completed | Phase 2 | 167 | Genentech, Inc.INDUSTRY | 0 | May 16, 2017 | clinicaltrials |
| NCT01122901 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma | terminated | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | May 3, 2017 | clinicaltrials |
| NCT02550249 | Neoadjuvant Nivolumab in Glioblastoma(Neo-nivo) | completed | Phase 2 | 29 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT00379080 | Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01268566 | A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 62 | MedImmune LLCINDUSTRY | 1 | Apr 6, 2017 | clinicaltrials |
| NCT00883298 | Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 30 | Center for Neurosciences, TucsonOTHER | 1 | Mar 30, 2017 | clinicaltrials |
| NCT01280552 | A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM) | completed | Phase 2 | 124 | Precision Life Sciences GroupINDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT00459381 | Pazopanib in Treating Patients With Recurrent Glioblastoma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00456612 | Radiosurgery for Glioblastoma Multiforme | terminated | Phase 1 / Phase 2 | 4 | Beth Israel Deaconess Medical CenterOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT01738646 | Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients | completed | Phase 2 | 48 | Duke UniversityOTHER | 1 | Mar 6, 2017 | clinicaltrials |
| NCT00171938 | Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors) | terminated | Phase 2 | 30 | NovartisINDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT02876003 | Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma | withdrawn | Phase 2 | 0 | GenSpera, Inc.INDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT02025231 | Image Guided Reirradiation of High-grade Glioma | terminated | Phase 1 / Phase 2 | 31 | Rigshospitalet, DenmarkOTHER | 2 | Feb 8, 2017 | clinicaltrials |
| NCT00813943 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status(CORE) | completed | Phase 2 | 265 | EMD SeronoINDUSTRY | 2 | Jan 30, 2017 | clinicaltrials |
| NCT02394665 | Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma | terminated | Phase 2 | 1 | University of MiamiOTHER | 1 | Jan 5, 2017 | clinicaltrials |
| NCT00085540 | FR901228 in Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 2, 2017 | clinicaltrials |
| NCT01443676 | Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma(ARTE) | completed | Phase 2 | 75 | University of ZurichOTHER | 1 | Nov 1, 2016 | clinicaltrials |
| NCT00574964 | Gliadel Wafers and Temodar in the Treatment of Glioblastoma Multiforme(Temodar) | terminated | Phase 2 | 50 | University of IowaOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT02939378 | Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study(KGDinrGBM) | unknown | Phase 1 / Phase 2 | 60 | Song LinOTHER | 1 | Oct 20, 2016 | clinicaltrials |
| NCT02104882 | INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study | completed | Phase 1 / Phase 2 | 12 | Universitätsmedizin MannheimOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT02928575 | Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma | unknown | Phase 2 | 45 | Bassam AbdulkarimOTHER | 1 | Oct 10, 2016 | clinicaltrials |
| NCT02898012 | Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status(ATAG) | completed | Phase 2 | 70 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 13, 2016 | clinicaltrials |
| NCT00544817 | Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme | completed | Phase 2 | 47 | SCRI Development Innovations, LLCOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT00302159 | Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors | completed | Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2016 | clinicaltrials |
| NCT01331291 | Bosutinib in Adult Patients With Recurrent Glioblastoma | completed | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT02815410 | Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients | unknown | Phase 2 | 73 | Seoul National University HospitalOTHER | 0 | Jun 28, 2016 | clinicaltrials |
| NCT02060955 | Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan | terminated | Phase 2 | 25 | CytoVac A/SINDUSTRY | 1 | Jun 6, 2016 | clinicaltrials |
| NCT00267592 | Safety and Efficacy of Talampanel in Glioblastoma Multiforme | completed | Phase 2 | 72 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | May 19, 2016 | clinicaltrials |
| NCT01213407 | Dendritic Cell Cancer Vaccine for High-grade Glioma(GBM-Vax) | completed | Phase 2 | 87 | Activartis BiotechINDUSTRY | 1 | May 19, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Nov 1, 2017source: clinicaltrials